EGLN2 and prostate carcinoma: Furthermore, clinical analyses across multiple prostate cancer cohorts (Broad_NG2012 [50], CPGEA [22], DKFZ [51], FHCRC [52], GSE62872 [53], MCTP [44], MSKCC [54], NPC [55], SMMU [56], and TCGA [57]) revealed significant positive correlations between HIF1α/PHD1 expression and EMT scores [58], cell cycle progression (CCP) scores [59], mesenchymal markers, and EMT-associated transcription factors.